TOKYO & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio Company Limited (hereafter, “the Company”) hereby announces that it entered into a business partnership agreement with D&P Bioinnovations, Inc.
LECO’s Citius™ LC-HRT High Resolution Time-of-Flight Mass Spectrometer offers an inherent advantage over traditional Q-TOF instrumentation with its unique MSc2 fragmentation technology. This novel ...
TOKYO--(BUSINESS WIRE)--The SanBio Group, a scientific leader in regenerative medicine for neurological disorders, today announced the acquisition of a patent portfolio regarding cell medicines ...
LECO’s Citius™ LC-HRT High Resolution Time-of-Flight Mass Spectrometer offers an inherent advantage over traditional Q-TOF instrumentation with its unique MSc2 fragmentation technology. This novel ...
Under the partnership agreement, SanBio will grant D&P a non-exclusive, non-transferable license to use MSC2 for the development and commercialization of the latter’s regenerative esophageal implant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results